Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alobresib + enzalutamide
- Development stage
- Preclinical
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Alobresib + enzalutamide** is an investigational combination therapy composed of alobresib (a BET bromodomain inhibitor) and enzalutamide (a second-generation androgen receptor inhibitor). This combination is under clinical investigation mainly for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Alobresib inhibits the bromodomain and extra-terminal motif (BET) proteins, thereby reducing the expression and signaling of the androgen receptor (AR) including splice variant AR-V7 that drives resistance to standard AR-directed therapies. Enzalutamide inhibits androgen receptor signaling by binding to the receptor, blocking androgen-induced receptor translocation and DNA binding. The rationale for combination is that BET inhibition may overcome resistance to AR antagonists by reducing AR signaling and associated resistance pathways.
- Brand names
- enzalutamide
- Other names
- BET inhibitor + enzalutamide
02
Targets
AR (Adrenergic receptors)BRD4 (Bromodomain-containing protein 4)
Beyond the preview
Go deeper on alobresib + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alobresib + enzalutamide.